Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RDY 
Dr. Reddy’s Laboratories Ltd ADR (RDY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: RDY (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15.15
1 Year Target Price $15.15
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 25.67% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.51B USD | Price to earnings Ratio 19.03 | 1Y Target Price 15.15 |
Price to earnings Ratio 19.03 | 1Y Target Price 15.15 | ||
Volume (30-day avg) 4 | Beta 0.39 | 52 Weeks Range 12.26 - 16.89 | Updated Date 07/1/2025 |
52 Weeks Range 12.26 - 16.89 | Updated Date 07/1/2025 | ||
Dividends yield (FY) 0.63% | Basic EPS (TTM) 0.79 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 17.37% | Operating Margin (TTM) 20.4% |
Management Effectiveness
Return on Assets (TTM) 10.37% | Return on Equity (TTM) 18.53% |
Valuation
Trailing PE 19.03 | Forward PE 18.52 | Enterprise Value 12368658465 | Price to Sales(TTM) 0.04 |
Enterprise Value 12368658465 | Price to Sales(TTM) 0.04 | ||
Enterprise Value to Revenue 3.25 | Enterprise Value to EBITDA 10.93 | Shares Outstanding 832129984 | Shares Floating 595031981 |
Shares Outstanding 832129984 | Shares Floating 595031981 | ||
Percent Insiders - | Percent Institutions 13.85 |
Analyst Ratings
Rating 1 | Target Price 15.15 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Dr. Reddy’s Laboratories Ltd ADR
Company Overview
History and Background
Dr. Reddy's Laboratories was founded in 1984 by Dr. K. Anji Reddy. It began as a manufacturer of active pharmaceutical ingredients (APIs) and gradually expanded into formulations, generics, and biosimilars. Significant milestones include its initial public offering in 1993 and expansion into international markets.
Core Business Areas
- Generics: Manufacturing and marketing of generic pharmaceutical products across various therapeutic areas.
- Pharmaceutical Services and Active Ingredients (PSAI): Supplying APIs to other pharmaceutical companies.
- Proprietary Products: Development and commercialization of differentiated and innovative pharmaceutical products.
- Biosimilars: Development, manufacturing and marketing of biosimilar drugs, replicating complex biological drugs.
Leadership and Structure
The leadership team is headed by the CEO, with various functional heads managing different business segments. The organizational structure is typically divisional, aligned with its core business areas.
Top Products and Market Share
Key Offerings
- Generic Pharmaceuticals: A wide range of generic drugs across therapeutic areas like cardiovascular, anti-infectives, pain management, and oncology. Market share varies by product and region; information is not uniformly available for each product. Competitors include Teva, Mylan, and Sun Pharma.
- Omezeprazole: One of Dr. Reddy's early successful products, an omeprazole generic. Market share varies geographically. Competitors include other generic manufacturers.
- Biosimilars (e.g., Rituximab Biosimilar): Biosimilar versions of biologic drugs, targeting conditions like cancer and autoimmune diseases. Market share is growing rapidly. Competitors include Biocon, Amgen, and Sandoz.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and increasing competition from generic and biosimilar manufacturers. The industry is constantly evolving with new drug discoveries and technological advancements.
Positioning
Dr. Reddy's is positioned as a global pharmaceutical company with a focus on generics, APIs, and biosimilars. Its competitive advantages include strong R&D capabilities, a diversified product portfolio, and a presence in both developed and emerging markets.
Total Addressable Market (TAM)
The global pharmaceuticals market is valued at over $1 trillion. Dr. Reddy's is well-positioned to capture a significant share of this market through its diversified portfolio and global presence.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities
- Diversified product portfolio
- Global presence
- Strong API manufacturing capabilities
- Established brand reputation
Weaknesses
- Dependence on generics market
- Exposure to regulatory risks
- Fluctuations in currency exchange rates
- High marketing expenses
Opportunities
- Growing demand for generics in emerging markets
- Increasing adoption of biosimilars
- Strategic acquisitions and partnerships
- Expanding into new therapeutic areas
Threats
- Intense competition from other generic manufacturers
- Pricing pressure from governments and payers
- Patent expirations
- Regulatory changes
Competitors and Market Share
Key Competitors
- TEVA
- MYL
- RDY
Competitive Landscape
Dr. Reddy's competes with other generic and branded pharmaceutical companies. Its advantages include a diversified product portfolio and a strong presence in emerging markets. Disadvantages include dependence on generics and exposure to regulatory risks.
Major Acquisitions
OctoPlus
- Year: 2010
- Acquisition Price (USD millions): 37
- Strategic Rationale: Strengthened drug delivery capabilities, particularly in complex generics.
Growth Trajectory and Initiatives
Historical Growth: Dr. Reddy's has experienced growth through new product launches, geographic expansion, and strategic acquisitions. Growth rates have fluctuated depending on market conditions and competitive pressures.
Future Projections: Future growth projections depend on various factors, including new product approvals, market penetration, and regulatory changes. Analyst estimates would need to be gathered to provide specific projections.
Recent Initiatives: Recent strategic initiatives include investments in R&D, expansion into new markets, and acquisitions of complementary businesses.
Summary
Dr. Reddy's Laboratories is a global pharmaceutical company with a diversified portfolio and strong R&D capabilities. While it benefits from the growing demand for generics and biosimilars, it faces intense competition and pricing pressure. The company's strategic initiatives and investments in innovation are crucial for future growth. It is a good company but faces challenges from competitors and market pressures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Analyst estimates
- SEC filings
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Investment decisions should be based on individual research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dr. Reddy’s Laboratories Ltd ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 2001-04-11 | CEO & Member of the Management Council Mr. Erez Israeli M.B.A. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 27811 | Website https://www.drreddys.com |
Full time employees 27811 | Website https://www.drreddys.com | ||
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.